Cite

HARVARD Citation

    André, F. et al. (n.d.). Ribociclib + letrozole for first-line treatment of HR+, HER2− ABC: efficacy, safety, and pharmacokinetics. European journal of cancer. pp. S7-. [Online]. 
  
Back to record